Adebrelimab with trastuzumab rezetecan for HER2-positive stage III lung cancer
Treatments studied
This trial is testing a combination of two drugs (adebrelimab and trastuzumab rezetecan) for people with stage III lung cancer that has a HER2 alteration. The tumor must be unresectable (not removable by surgery). Participants must not have had prior systemic treatment for their lung cancer. They need to have measurable disease and be in generally good health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Aged 18 to 75 years
- Stage III non-small cell lung cancer not amenable to surgery
- Tumor tests positive for HER2 alteration (mutation, amplification, or overexpression)
- No prior systemic treatment for lung cancer (herbal medicine allowed with a 2-week washout)
- At least one measurable tumor on imaging
- ECOG performance status 0 or 1
- Adequate organ function (blood counts, liver, kidney, heart) as per trial protocol
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a targeted drug called trastuzumab deruxtecan in people with advanced non-small cell lung cancer that has high levels of a protein called HER2. It may be an option if your cancer has grown after at least one prior treatment.
This trial tests a combination of two drugs (SHR-A1811 and Adebelimumab) given before surgery for people with a specific type of lung cancer that has changes in the HER2 gene. The goal is to see if this treatment can shrink the tumor and make surgery more effective.
This trial tests adding the immunotherapy drug Adebrelimab to standard chemotherapy before surgery for people with stage II or III non-small cell lung cancer (the most common type) that can be removed. The goal is to see if this combination shrinks tumors more effectively and improves outcomes.
This study tests a combination of two newer drugs (trastuzumab rezetecan and ivonescimab) for advanced non-small cell lung cancer whose cancer cells have a specific HER2 gene change. The trial includes two groups: people who have already tried one round of treatment, and people newly diagnosed who haven't had treatment yet.
This trial tests a new combination of drugs (trastuzumab deruxtecan, pembrolizumab, and chemotherapy) as a first treatment for people with advanced non-small cell lung cancer that has high levels of the HER2 protein. The goal is to see if this combination works better than current options.
This trial tests a new targeted therapy combined with radiation for people with HER2-mutated lung cancer that is progressing only in a few spots. It aims to see if this combination can help keep the cancer under control and improve outcomes.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.